{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.99","value":"2.42"},{"groupId":"OG001","spread":"4.48","value":"0.80"}]}],"title":"Global Health Status/QoL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.20","value":"-6.26"},{"groupId":"OG001","spread":"4.82","value":"-12.01"}]}],"title":"Physical Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.65","value":"-4.32"},{"groupId":"OG001","spread":"6.99","value":"-11.79"}]}],"title":"Role Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.29","value":"-1.61"},{"groupId":"OG001","spread":"4.92","value":"-6.51"}]}],"title":"Emotional Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.63","value":"-4.26"},{"groupId":"OG001","spread":"3.94","value":"-10.94"}]}],"title":"Cognitive Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.90","value":"-1.98"},{"groupId":"OG001","spread":"5.86","value":"-1.37"}]}],"title":"Social Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.43","value":"3.16"},{"groupId":"OG001","spread":"5.16","value":"6.88"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.86","value":"1.77"},{"groupId":"OG001","spread":"4.32","value":"2.88"}]}],"title":"Nausea and Vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.61","value":"0.13"},{"groupId":"OG001","spread":"5.42","value":"3.85"}]}],"title":"Pain"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.35","value":"-2.61"},{"groupId":"OG001","spread":"5.08","value":"3.51"}]}],"title":"Dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.19","value":"-7.47"},{"groupId":"OG001","spread":"6.28","value":"-3.95"}]}],"title":"Insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.60","value":"-1.01"},{"groupId":"OG001","spread":"6.91","value":"7.16"}]}],"title":"Appetite Loss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.79","value":"0.09"},{"groupId":"OG001","spread":"5.69","value":"7.94"}]}],"title":"Constipation"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.64","value":"-3.97"},{"groupId":"OG001","spread":"2.46","value":"-5.49"}]}],"title":"Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.78","value":"-12.86"},{"groupId":"OG001","spread":"5.68","value":"-2.39"}]}],"title":"Financial Difficulties"}],"denoms":[{"counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"description":"EORTC QLQ-C30 v3.0 is a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, cognitive, emotional, and social), global health status, and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms. Best change from baseline results determined by Least Square (LS) mean estimated with randomization stratification factors and baseline value as continuous covariate.","dispersionType":"Standard Error","groups":[{"description":"Participants received IMC-1121B (ramucirumab), administered via intravenous infusion every 2 weeks at a dose of 8 milligrams/kilogram (mg/kg), plus best supportive care (BSC) as determined by the investigator(s). Treatment continued until there was evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.","id":"OG000","title":"IMC-1121B (Ramucirumab)"},{"description":"Participants received placebo by intravenous infusion every 2 weeks plus best supportive care as determined appropriate by the investigator(s). Because investigators and ancillary medical personnel were blinded as to assignment to active therapy versus placebo, the volume of placebo administered was calculated as if it were active product with a dose of 8 mg/kg. Treatment continued until there was evidence of PD, the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.","id":"OG001","title":"Placebo"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"All randomized participants with EORTC QLQ-C30 values at baseline and any point up to 18 weeks post-baseline.","reportingStatus":"POSTED","timeFrame":"Baseline up to Cycle 10 (18 weeks [1 cycle=2 weeks])","title":"Change From Baseline in Quality of Life (QoL) as Measured by the European Organisation for Research and Treatment of Cancer Questionnaire (EORTC-QLQ-C30)","type":"SECONDARY","unitOfMeasure":"units on a scale"}